Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Daraprim Generic Name & Formulations
Legal Class
Rx
General Description
Pyrimethamine 25mg; scored tabs.
Pharmacological Class
Folic acid antagonist.
How Supplied
Tabs—30, 100
Manufacturer
Generic Availability
NO
Daraprim Indications
Indications
Treatment of acute malaria in combination with other antimalarials only. Chemoprophylaxis of malaria due to susceptible strains of plasmodia.
Daraprim Dosage and Administration
Adults and Children
Acute treatment: Monotherapy not recommended, must give with concomitant fast-acting schizonticides (eg, chloroquine, quinine). 25mg daily for 2 days with a sulfonamide. Monotherapy in semi-immune adult patients (should circumstances arise): 50mg daily for 2 days; children 4–10yrs: 25mg daily for 2 days. Chemoprophylaxis: <4yrs: 6.25mg once weekly. 4–10yrs: 12.5mg once weekly. >10yrs: 25mg once weekly. Regimens which include suppression should be extended through any characteristic periods of early recrudescence and late relapse, for at least 10 weeks in each case.
Daraprim Contraindications
Contraindications
Megaloblastic anemia due to folate deficiency.
Daraprim Boxed Warnings
Not Applicable
Daraprim Warnings/Precautions
Warnings/Precautions
Renal or hepatic impairment. Folate deficiency (eg, malabsorption syndrome, alcoholism, pregnancy, concomitant phenytoin). Pregnancy (Cat.C). Nursing mothers: not recommended.
Daraprim Pharmacokinetics
See Literature
Daraprim Interactions
Interactions
Increased risk of bone marrow suppression with concomitant antifolic drugs or agents associated with myelosuppression (eg, sulfonamides, trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, methotrexate). Mild hepatotoxicity with lorazepam.
Daraprim Adverse Reactions
Adverse Reactions
Hypersensitivity reactions (may be severe: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, anaphylaxis; discontinue if occurs), hyperphenylalaninemia, hematologic effects; rare: pulmonary eosinophilia. May be carcinogenic.
Daraprim Clinical Trials
See Literature
Daraprim Note
Not Applicable
Daraprim Patient Counseling
See Literature
Daraprim Generic Name & Formulations
Legal Class
Rx
General Description
Pyrimethamine 25mg; scored tabs.
Pharmacological Class
Folic acid antagonist.
How Supplied
Tabs—30, 100
Manufacturer
Generic Availability
NO
Daraprim Indications
Indications
Treatment of toxoplasmosis when used conjointly with a sulfonamide.
Daraprim Dosage and Administration
Adult
Give concomitant folinic acid. Initially 50–75mg daily, together with 1–4g daily of a sulfonamide of the sulfapyramidine type (eg, sulfadoxine). Continue for 1–3 weeks depending on response and tolerance. May reduce dose by ½ and continue for additional 4–5 weeks.
Children
Give concomitant folinic acid and usual pediatric sulfonamide dose. 1mg/kg divided into 2 equal doses; after 2–4 days, may reduce dose by ½ and continue for 1 month.
Daraprim Contraindications
Contraindications
Megaloblastic anemia due to folate deficiency.
Daraprim Boxed Warnings
Not Applicable
Daraprim Warnings/Precautions
Warnings/Precautions
Renal or hepatic impairment. Folate deficiency (eg, malabsorption syndrome, alcoholism, pregnancy, concomitant phenytoin); reduce dose or discontinue drug if develops. Seizure disorders: give small starting dose to avoid CNS toxicity. Obtain semi-weekly blood counts, including platelets. Pregnancy (Cat.C). Nursing mothers: not recommended.
Daraprim Pharmacokinetics
See Literature
Daraprim Interactions
Interactions
Increased risk of bone marrow suppression with concomitant antifolic drugs or agents associated with myelosuppression (eg, sulfonamides, trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, methotrexate). Mild hepatotoxicity with lorazepam.
Daraprim Adverse Reactions
Adverse Reactions
Hypersensitivity reactions (may be severe: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, anaphylaxis; discontinue if occurs), hyperphenylalaninemia, hematologic effects (eg, megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia), atrophic glossitis, hematuria, cardiac rhythm disorders; rare: pulmonary eosinophilia. May be carcinogenic.
Daraprim Clinical Trials
See Literature
Daraprim Note
Not Applicable
Daraprim Patient Counseling
See Literature
